NDA 208051 · Puma Biotech
Nerlynx
Neratinib Maleate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jun 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jul 17, 2017
Approved uses
6
Original approval plus efficacy supplements
Registered trials
92
5 Phase 3, 21 recruiting
FAERS reports
2,319
1,373 serious, 364 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 2, 2026.
NERLYNX is a kinase inhibitor indicated: As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy. ( 1.1 ) In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. ( 1.2 ) 1.1 Extended Adjuvant Treatment of Early-Stage Breast Cancer NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, to follow adjuvant trastuzumab based therapy [see Clinical Studies ( 14.1 )] . 1.2 Advanced or Metastatic Breast Cancer NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting [see Clinical Studies ( 14.2 )] .
Mechanism: Neratinib is an intracellular kinase inhibitor that irreversibly binds to epidermal growth factor receptor (EGFR), HER2, and HER4. In vitro , neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7 and M11 inhibited the activity of EGFR, HER2, and HER4 in vitro. In vivo , oral administration of neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 28, 2021 Supplement 9 · Efficacy LabelLetter
- Jul 29, 2020 Supplement 7 · Efficacy LetterLabel
- Feb 25, 2020 Supplement 5 · Efficacy LetterLabel
- Feb 25, 2020 Supplement 6 · Efficacy LetterLabel
- Oct 1, 2019 Supplement 4 · Efficacy LetterLabel
- Jul 17, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- NERLYNX · NERATINIB MALEATE EQ 40MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Neratinib" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerPivotal-lookingCompleted
Puma Biotechnology, Inc.Industry
NCT00878709 · 2,840 participants · Start Jul 9, 2009 · Primary completion Aug 21, 2014
Drug: neratinib · For: Breast Cancer
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 494 sites in all
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT03182634 · 1,150 participants (planned) · Start Dec 15, 2016 · Primary completion Nov 2022
Drug: Fulvestrant; Neratinib and 3 more · For: Advanced Breast Cancer
Sites: Sutton, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 19 sites in all
- Personalized Medicine for Advanced Biliary Cancer PatientsPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT05615818 · 800 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 2027
Drug: Futibatinib; Ivosidenib and 8 more · For: Biliary Tract Neoplasms
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 69 sites in all
- A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic SettingPivotal-lookingCompleted
Puma Biotechnology, Inc.Industry
NCT01808573 · 621 participants · Start Mar 29, 2013 · Primary completion Sep 28, 2018
Drug: neratinib; capecitabine and 1 more · For: HER2+ Metastatic Breast Cancer (MBC)
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 252 sites in all
Puma Biotechnology, Inc.Industry
NCT01953926 · 582 participants · Start Sep 30, 2013 · Primary completion Jan 2, 2023
Drug: Neratinib; Fulvestrant and 2 more · For: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 60 sites in all
Puma Biotechnology, Inc.Industry
NCT02400476 · 563 participants · Start Feb 2015 · Primary completion Apr 22, 2021
Drug: Neratinib; Loperamide and 2 more · For: Early Stage HER2+ Breast Cancer
Sites: Birmingham, Alabama; Corona, California; Fullerton, California · 58 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea1,262
- nausea557
- fatigue474
- off label use414
- vomiting317
- constipation279
- decreased appetite257
- death199
- disease progression157
- dehydration148
- weight decreased139
- abdominal pain119
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 3 |
| 2010 | 23 |
| 2011 | 10 |
| 2012 | 13 |
| 2013 | 16 |
| 2014 | 8 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 143 |
| 2018 | 739 |
| 2019 | 241 |
| 2020 | 255 |
| 2021 | 280 |
| 2022 | 170 |
| 2023 | 147 |
| 2024 | 124 |
| 2025 | 84 |
| 2026 | 57 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nerlynx (Neratinib Maleate)
2024 spending
$38.4M
Beneficiaries
466
2,103 claims
Per beneficiary
$82,403
$121.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $42,196,972 |
| 2021 | $30,227,649 |
| 2022 | $31,488,068 |
| 2023 | $36,541,269 |
| 2024 | $38,400,021 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.
Kerr AJ, Dodwell D, McGale P, et al. · Cancer Treat Rev 2022 · Systematic Review
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM, Piha-Paul SA, Won H, et al. · Nature 2018 · Clinical Trial, Research Support, N.I.H., Extramural
- Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N · Breast 2022 · Meta-Analysis
- Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan A, Moy B, Mansi J, et al. · Clin Breast Cancer 2021 · Clinical Trial, Phase III, Multicenter Study
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A, Delaloge S, Holmes FA, et al. · Lancet Oncol 2016 · Clinical Trial, Phase III, Multicenter Study
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, et al. · Lancet Oncol 2017 · Clinical Trial, Phase III, Comparative Study
Sponsor: Puma Biotech
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.